We understand that registering for a conference is not essential right now and many researchers will be unable to register for a future conference of interest if their university or lab is temporarily closed. Therefore, you can simply register your interest here to be kept updated with details about this conference without committing to attending and our team will keep in touch with you regarding deadline reminders and grant opportunities. If you are looking to register to take advantage of the earlybird deadline or if you wish to submit an abstract, but you cannot pay the minimum deposit at this time, please contact us for a registration link which will allow you to register without a deposit. We hope these services are helpful during this difficult time.
Defects in DNA damage repair and checkpoint control are underlying mechanisms driving tumorigenesis, since they allow for the accumulation of genetic alternations. In addition, defects associated with these pathways are the underlying cause of several human cancer-prone syndromes. On the other hand, defects in DNA repair and checkpoint control create vulnerabilities in cancer cells that can be targeted by DNA damaging agents and inhibitors that disrupt checkpoint pathways. This conference will focus on exploring these vulnerabilities, taking advantage of the synthetic lethality concept and targeting particular DNA repair and checkpoint pathways for cancer therapy. This conference will bring together basic, translational and clinical investigators to discuss current and future directions, opportunities and obstacles to the development of these anti-cancer modalities and how to best translate these concepts to clinical practice.
Confirmed Invited Speakers
Chuna Choudhary (University of Copenhagen)
Daniel Durocher (Lunenfeld-Tanenbaum Research Institute)
DISCOVERY OF SYNTHETIC LETHAL INTERACTIONS IN DNA REPAIR PATHWAYS
Mark O'Connor (AstraZeneca)
Agata Smogorzewska (The Rockefeller University)
Steve West (Francis Crick Institute)
SPECIFIC KILLING OF BRCA-DEFICIENT CELLS BY TARGETING NUCLEOTIDE SALVAGE PATHWAYS
Shannon Westin (UT MD Anderson Cancer Center )
- Highlight recent advances in the field of DNA damage repair
- Identify novel targets in DNA repair and checkpoint pathways
- Explore the concept of synthetic lethality for cancer treatment
- Assess the therapeutic potential of new anti-cancer modalities
- Discuss mechanisms of therapeutic resistance and ways to improve cancer therapy
Take advantage of this fantastic opportunity for students! Fully paying academics can bring a student for only $890. Unfortunately, Postdocs are not eligible. Both registration packages include; accommodation for the 17, 18, 19 February 2022 (on a shared basis for students) and a food and beverage package for the conference period. Once registered, please contact Jack Peters to obtain a special registration link for your student.
This conference explores topics that should appeal to basic, translational, clinical investigators as well as clinicians ranging from academics to industry.
DNA damage repair and checkpoint control is an exciting field that has undergone tremendous growth in the past few years. While insightful new research on the molecular mechanisms that govern a variety of DNA repair and cell cycle checkpoint pathways has led to an expansion of our understanding of DNA damage response pathways in humans, it also offers new approaches for cancer prevention and treatment. The purpose of this conference is to accelerate the translation of basic research findings into clinical practice. The audience will benefit from the interactions with experts in the fields of DNA damage response, drug development and clinical trials.